{"drugs":["Cabozantinib Malate","Cometriq"],"mono":{"0":{"id":"930355-s-0","title":"Generic Names","mono":"Cabozantinib Malate"},"1":{"id":"930355-s-1","title":"Dosing and Indications","sub":[{"id":"930355-s-1-4","title":"Adult Dosing","mono":"<b>Medullary thyroid carcinoma, Progressive, metastatic:<\/b> 140 mg ORALLY once daily until disease progression or unacceptable toxicities; take on an empty stomach "},{"id":"930355-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"930355-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment, moderate or severe:<\/b> not recommended<\/li><li><b>hematologic toxicity, grade 4:<\/b> withhold dose; after return to baseline or grade 1, resume treatment at reduced dosage (ie, 100 mg orally once daily for patients previously taking 140 mg\/day; 60 mg orally once daily for patients previously taking 100 mg\/day or 60 mg\/day)<\/li><li><b>non-hematologic toxicity, grade 3 or greater or intolerable grade 2:<\/b> after return to baseline or grade 1, resume treatment at reduced dosage (ie, 100 mg orally once daily for patients previously taking 140 mg\/day; 60 mg orally once daily for patients previously taking 100 mg\/day or 60 mg\/day)<\/li><li><b>concomitant use with strong CYP3A4 inhibitors:<\/b> avoid use if possible; if concomitant use required, reduce the daily cabozantinib dose by 40 mg; resume the cabozantinib dose that was used prior to the initiation of the CYP3A4 inhibitor 2 to 3 days after discontinuation of the CYP3A4 inhibitor<\/li><li><b>concomitant use with strong CYP3A4 inducers:<\/b> avoid chronic use of strong CYP3A4 inducers if alternative therapy is available; if concomitant use is required, increase the daily cabozantinib dose by 40 mg as tolerated (maximum cabozantinib dose, 180 mg); resume the cabozantinib dose that was used prior to the initiation of the CYP3A4 inducer 2 to 3 days after discontinuation of the CYP3A4 inducer; also avoid the use of St. John's wort<\/li><\/ul>"},{"id":"930355-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Medullary thyroid carcinoma, Progressive, metastatic<br\/>"}]},"2":{"id":"930355-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>Gastrointestinal (GI) perforations, fistula formation, and severe hemorrhage have occurred in patients treated with cabozantinib malate. Discontinue therapy if GI perforation or fistula develop. Monitor patients for bleeding, and do not administer cabozantinib malate to patients with severe hemorrhage.<br\/>"},"3":{"id":"930355-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930355-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930355-s-3-10","title":"Precautions","mono":"<ul><li>gastrointestinal perforation and fistula formation, including fatal cases, have occurred; monitoring required; discontinuation recommended<\/li><li>hemorrhage, serious and sometimes fatal, has occurred; do not administer to patients with recent history of hemorrhage or hemoptysis; discontinue if severe hemorrhage develops<\/li><li>concomitant use with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) should be avoided<\/li><li>concomitant use with strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) should be avoided<\/li><li>dental procedures, invasive; increased risk for osteonecrosis of the jaw; withhold therapy for at least 28 days prior to scheduled surgery if possible<\/li><li>hepatic impairment, moderate to severe; use not recommended<\/li><li>hypertension, treatment-emergent, has been reported; monitoring recommended; temporarily withhold therapy for hypertension not controlled with medical management; discontinue therapy for malignant hypertension, hypertensive crisis, or persistent uncontrolled hypertension despite medical management<\/li><li>osteonecrosis of the jaw has been reported; increased risk with poor oral hygiene; monitoring recommended<\/li><li>palmar-plantar erythrodysesthesia syndrome has occurred; therapy interruption and dose reduction may be required<\/li><li>pregnancy should be avoided; known teratogen<\/li><li>proteinuria, including nephrotic syndrome, has occurred; monitoring recommended; discontinue therapy if nephrotic syndrome occurs<\/li><li>reversible posterior leukoencephalopathy syndrome (RPLS) has occurred; discontinue therapy if RPLS occurs<\/li><li>thromboembolism, including arterial and venous events, has occurred; discontinue use in patients with clinically significant arterial thrombotic complication, including acute myocardial infarction<\/li><li>wound healing complications have occurred; discontinue use at least 28 days prior to scheduled surgery and resume therapy upon adequate wound healing; withhold therapy if wound dehiscence or healing complications occur<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930355-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"930355-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930355-s-4","title":"Drug Interactions","sub":{"1":{"id":"930355-s-4-14","title":"Major","mono":"<ul><li>Aprepitant (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}}},"5":{"id":"930355-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (33%)<\/li><li><b>Dermatologic:<\/b>Hair color change (34%)<\/li><li><b>Endocrine metabolic:<\/b>Hypocalcemia (52%), Hypophosphatemia (28%), Weight loss (48%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (27%), Constipation (27%), Decrease in appetite (46%), Dental pain (36%), Diarrhea (63%), Nausea (43%), Stomatitis (51%), Taste sense altered (34%)<\/li><li><b>Hematologic:<\/b>Lymphocytopenia, All grades (53%), Neutropenia, All grades (35%), Thrombocytopenia, All grades (35%)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised (52%), ALT\/SGPT level raised (86%), AST\/SGOT level raised (86%), Hyperbilirubinemia (25%)<\/li><li><b>Other:<\/b>Fatigue (41%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Hand-foot syndrome due to cytotoxic therapy (50%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal fistula (1%), Gastrointestinal perforation (3%), Tracheoesophageal fistula (4%)<\/li><li><b>Hematologic:<\/b>Arterial thromboembolism (2%), Bleeding, Grade 3 or higher (3%), Lymphocytopenia, Grade 3 or 4 (16%), Neutropenia, Grade 3 or 4 (3%), Venous thromboembolism (6%)<\/li><li><b>Musculoskeletal:<\/b>Aseptic necrosis of bone of jaw (1%)<\/li><li><b>Neurologic:<\/b>Posterior reversible encephalopathy syndrome (less than 1%)<\/li><\/ul>"},"6":{"id":"930355-s-6","title":"Drug Name Info","sub":{"0":{"id":"930355-s-6-17","title":"US Trade Names","mono":"Cometriq<br\/>"},"2":{"id":"930355-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Tyrosine Kinase Inhibitor<\/li><\/ul>"},"3":{"id":"930355-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930355-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930355-s-7","title":"Mechanism Of Action","mono":"Cabozantinib is an inhibitor of multiple tyrosine kinases that is indicated for the treatment of metastatic thyroid carcinoma. It inhibits RET, MET, vascular endothelial growth factor receptors 1, 2 and 3, KIT, TRKB, FLT-3, AXL, and TIE-2.<br\/>"},"8":{"id":"930355-s-8","title":"Pharmacokinetics","sub":[{"id":"930355-s-8-23","title":"Absorption","mono":"<ul><li>Tmax: 2 to 5 hours<\/li><li>Effects of food: increased Cmax by 41%; increased AUC by 57%<\/li><\/ul>"},{"id":"930355-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, plasma proteins: 99.7% or greater<\/li><li>Vd: 349 L<\/li><\/ul>"},{"id":"930355-s-8-25","title":"Metabolism","mono":"<ul><li>XL184 N-oxide metabolite: unknown activity<\/li><li>inducer of CYP1A1 in vitro<\/li><li>inhibitor of CYP2C8, CYP2C9, CYP2C19, and P-glycoprotein in vitro<\/li><li>substrate of CYP3A4 in vitro<\/li><\/ul>"},{"id":"930355-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 54%<\/li><li>Renal: 27%<\/li><li>Total body clearance: 4.4 L\/hr<\/li><\/ul>"},{"id":"930355-s-8-27","title":"Elimination Half Life","mono":"55 hours <br\/>"}]},"9":{"id":"930355-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>do not eat for 2 hours before and 1 hour after taking cabozantinib<\/li><li>swallow capsules whole; do not open capsule<\/li><\/ul>"},"10":{"id":"930355-s-10","title":"Monitoring","mono":"<ul><li>evidence of disease response or stabilization indicates efficacy<\/li><li>urine protein levels, regularly<\/li><li>bleeding signs and symptoms, especially gastrointestinal hemorrhage and hemoptysis<\/li><li>fistula or perforation signs and symptoms<\/li><li>blood pressure, before drug initiation and regularly during therapy<\/li><\/ul>"},"11":{"id":"930355-s-11","title":"How Supplied","mono":"<b>Cometriq<\/b><br\/>Oral Capsule: 20 MG<br\/>"},"13":{"id":"930355-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel female patient to use reliable contraception during therapy and for at least 4 months after drug discontinuation.<\/li><li>Tell patient to report symptoms of perforations, fistulas, hemorrhages or thrombotic events (myocardial infarction, thromboembolism).<\/li><li>Instruct patient to report symptoms of palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome).<\/li><li>Warn patient to report symptoms of reversible posterior leukoencephalopathy syndrome (seizures, headache, altered mental function, confusion, visual disturbances).<\/li><li>Drug may cause diarrhea, constipation, nausea, abdominal pain, dysgeusia, stomatitis, decreased appetite, weight loss, fatigue, and changes in hair color.<\/li><li>Instruct patient to report symptoms of osteonecrosis of the jaw and to practice good oral hygiene.<\/li><li>Tell patient to take drug on an empty stomach, with no food at least 2 hours before and 1 hour after administration.<\/li><li>Instruct patient that drug discontinuation is necessary before elective surgery or invasive dental procedures.<\/li><li>Counsel patient to avoid grapefruit or grapefruit juice with this drug.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs, such as St. John's Wort).<\/li><\/ul>"}}}